227 related articles for article (PubMed ID: 34563208)
1. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Szymanski KM; Wei JT; Dunn RL; Sanda MG
Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
[TBL] [Abstract][Full Text] [Related]
4. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
[TBL] [Abstract][Full Text] [Related]
6. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
8. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
Lee WR; Hall MC; McQuellon RP; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):614-23. PubMed ID: 11597800
[TBL] [Abstract][Full Text] [Related]
9. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the University of California-Los Angeles Prostate Cancer Index.
Bergman J; Saigal CS; Kwan L; Litwin MS
Urology; 2010 Jun; 75(6):1418-23. PubMed ID: 19589573
[TBL] [Abstract][Full Text] [Related]
11. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
13. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
[TBL] [Abstract][Full Text] [Related]
14. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
[TBL] [Abstract][Full Text] [Related]
15. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
[TBL] [Abstract][Full Text] [Related]
16. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.
Sureda A; Fumadó L; Ferrer M; Garín O; Bonet X; Castells M; Mir MC; Abascal JM; Vigués F; Cecchini L; Suárez JF
Health Qual Life Outcomes; 2019 Jan; 17(1):11. PubMed ID: 30642340
[TBL] [Abstract][Full Text] [Related]
18. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
[TBL] [Abstract][Full Text] [Related]
19. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
[TBL] [Abstract][Full Text] [Related]
20. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
